Spexis Granted Definitive Moratorium Status Until November 2024

Spexis AG, a clinical-stage biopharmaceutical company, has been granted definitive moratorium status by the Basel-Landschaft West court until 25 November 2024. This decision is contingent upon monthly progress reports and may be extended upon the administrators’ request.

The court’s ruling follows a hearing held on 23 July 2024. During the moratorium, Spexis is required to submit periodic reports on its fundraising and corporate partnership efforts. Despite this extension, the court retains the authority to order liquidation or bankruptcy if the company fails to secure financing.

Spexis, focused on macrocycle therapeutics for rare diseases and oncology, is actively seeking to navigate this challenging period. Chair & CEO Jeff Wager expressed optimism about the decision, emphasizing ongoing efforts to secure favorable outcomes for creditors and shareholders.

The company acknowledges the patience of its stakeholders and commits to providing timely updates as the situation evolves.